The use of pharmacological inhibition of the NRG1-HER3 pathway with YW538.24.71 (NRG1-neutralizing antibody), AMG888 (HER3-blocking antibody), and neratinib (HER2 kinase inhibitor) significantly inhibited the growth of CWR22Pc tumor, a patient-derived xenograft model. Here, NRG1 is linked to neoplasm.